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ABSTRACT 
Background: Prolonged opioid administration leads to tolerance characterised by reduced analgesic 
potency. Pain management is additionally compromised by the hedonic effects of opioids, the cause of 
their misuse. The multifunctional protein β-arrestin2 regulates the hedonic effects of morphine and 
participates in tolerance. These actions might reflect µ opioid receptor up-regulation through reduced 
endocytosis. β-Arrestin2 also recruits kinases to µ receptors. We explored the role of Src kinase in 
morphine analgesic tolerance, locomotor stimulation and reinforcement in C57BL/6 mice. 
Methods: Analgesic (tail withdrawal latency; % maximum possible effect (MPE), n = 8-16), locomotor 
(distance travelled, n = 7-8) and reinforcing (conditioned place preference, n = 7-8) effects of morphine 
were compared in wild type, µ+/-, µ-/- and β-arrestin2-/- mice. The influence of c-Src inhibitors, dasatinib (n 
= 8) and PP2 (n = 12), were examined. 
Results: Analgesia in morphine treated wild type mice exhibited tolerance, declining by day 10 to a median 
of 62% MPE (interquartile range (IQR): 29-92). Tolerance was absent from mice receiving dasatinib. 
Tolerance was enhanced in µ+/- mice (34% MPE; IQR: 5-52 on day 5); dasatinib attenuated tolerance (100% 
MPE; IQR: 68-100) as did PP2 (91% MPE; IQR: 78-100). By contrast, c-Src inhibition neither affected 
morphine-evoked locomotor stimulation nor reinforcement. Remarkably, dasatinib not only attenuated 
tolerance, but also reversed established tolerance in µ+/- mice. 
Conclusions: The ability of c-Src inhibitors to inhibit tolerance, thereby restoring analgesia, without altering 
the hedonic effect of morphine, make c-Src inhibitors promising candidates as adjuncts to opioid 
analgesics. 
  
 
 
While estimates vary, 9% of Americans and 19% of Europeans (11 – 55% in developing countries) are 
reported to experience moderate to severe persistent pain.1 Many pain sufferers receive prolonged opioid 
administration. Unfortunately however, tolerance develops leading to the requirement for increasing 
opioid doses for adequate pain control.1,2 Opioid tolerance is associated with the development of 
dependence and unpleasant withdrawal when treatment stops. Additional complications of opioid 
analgesics include constipation and, at higher doses, respiratory depression.1 The requirement for 
escalating doses to maintain analgesia increases the potential for prescription opioid misuse, diversion and 
overdose.3,4 Despite intensive attempts to develop alternative analgesics, there are currently none to 
replace opioids in the treatment of severe pain. An alternative is to improve opioid analgesia, minimising 
activation of pathways responsible for their detrimental effects such as tolerance, either by seeking 
agonists biased against such pathways, or by inhibiting them with adjunct agents.5,6 
 
µ Opioid receptors mediate both the beneficial and the adverse effects of analgesic opioids.7 µ Receptors 
are G protein coupled receptors (GPCRs) that also recruit β-arrestin2, which participates in desensitisation, 
endocytosis and signalling through various kinases, including extracellular signal-regulated kinase (ERK) and 
the non-receptor tyrosine kinase, c-Src.2,8 Mice lacking β-arrestin2 (β-arr2-/- mice) exhibit reduced 
morphine tolerance and increased µ-receptor mediated basal nociception.9,10 The inhibition of several 
pathways that converge on c-Src also reduces morphine tolerance, implicating the tyrosine kinase as a 
potential hub for this process (fig. 1).  
 
The µ receptor-mediated activation of c-Src in primary afferent neurons requires β-arrestin2 and inhibition 
of c-Src causes reductions in µ receptor endocytosis and opioid-induced desensitisation.11,12 These 
observations led us to hypothesise that c-Src contributes to morphine tolerance. Given the evidence for a 
role of β-arrestin2 in the locomotor and reinforcing effects of morphine, we further hypothesised that c-Src 
also participates in these behaviours.13,14 Our findings suggest that c-Src inhibition suppresses tolerance 
without altering the locomotor or reinforcing effects of analgesic opioids. 
  
 
 
Materials and Methods 
Animals  
In this study we used µ+/-, µ-/- and β-arr2-/- mice maintained on the C57BL/6J background, in the 
Ninewells Hospital Medical Resource Unit in accordance with the local ethics committee and UK Home 
Office regulations with an appropriate project license. They had access to food and water ad libitum with 
12 hour cycles of light and dark, the temperature was maintained between 19 and 21°C. All experiments 
were performed in the light phase. Mice used in experiments were genotyped by Transnetyx (Cordova, TN, 
USA).  
 
Behavioural Tests  
Prior to each experiment, mice (aged 7-24 weeks, both sexes) were habituated. All experiments took place 
during the light phase. Drug doses were calculated using individual body weight and maximum volume 
administered in a single injection was 200 μL. Drug administration: Morphine sulphate (Sigma-Aldrich, 
Dorset, UK) was diluted in 0.9% NaCl in an aseptic environment and filtered using a 0.2 μm syringe filter 
prior to use. Morphine was administered subcutaneously (s.c.). For experiments involving c-Src inhibition, 
dasatinib (Bristol Myers Squibb, NY, USA), PP2 (Tocris, Bristol, UK) and PP3 (Tocris, Bristol, UK) were 
reconstituted in DMSO and Kolliphor EL (Sigma-Aldrich, Dorset, UK) and diluted in a 0.9% saline solution. 
Dasatinib (5 mg/Kg), its vehicle, PP2 (5 mg/Kg) and PP3 (5 mg/Kg) were administered via the intraperitoneal 
route (i.p.). Mice were randomly assigned to vehicle- or drug-treated groups while balancing the proportion 
of males and females. All samples were included for analysis with one exception: a mouse incorrectly 
assigned as µ-/-, which was omitted due to the initial genotyping error. During tail withdrawal assays the 
individual measuring the latency was blinded to the condition of the animal. Conditioned place preference 
and locomotor data were collected by CCTV and footage was analysed automatically by AnyMaze software 
(Stoelting Europe, Dublin, Ireland). Sample sizes were chosen based on our previous experience.10 
 
Tail Withdrawal Assay  
Morphine analgesia was assessed by measuring the latency for tail withdrawal from 48°C water 30 min 
after s.c. administration. Maximum exposure time to 48°C water was 15 s. We used an electronic 
thermostatic circulating water bath (Thermo Fisher, Loughborough, UK) to maintain water temperature 
within ± 0.1°C. Baseline tail withdrawal latencies were measured prior to the start of each experiment.  
 
Conditioned Place Preference  
We used a two compartment model of conditioned place preference to investigate morphine 
reinforcement in mice. One chamber had wall covering of black and white horizontal stripes and the other 
black and white vertical stripes. The compartments are contained within an operant box. These boxes are 
soundproofed and allow light levels to be controlled at approximately 70 lumens. The temperature was 
 
 
maintained between 21 and 23°C. Mice were habituated to the testing environment and allowed free 
access to both chambers prior to experiments. Mouse activity was recorded using a CCTV camera and 
parameters such as time spent in each chamber and distance travelled were acquired using AnyMaze 
software. During the 4-day conditioning period, all mice received s.c. injections of 0.9% saline (volume 
matched to that of the morphine injection) in either chamber. Four hours later the mice received an s.c. 
injection of morphine sulphate in the opposite chamber. After each injection they were confined to the 
corresponding chamber for 30 min. Between conditioning sessions mice were returned to their home 
cages. On day five mice were allowed free access to both chambers for 15 min. The time spent in each 
chamber was recorded using AnyMaze software.  
 
Cell Culture and Western Blots  
SW620 human colon cancer cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen) at 37°C and 
5% CO2.
15 Cell lysis was performed in RIPA buffer (Thermo-Fisher, Loughborough, UK). Proteins were 
separated using denaturing SDS-PAGE and transferred onto nitrocellulose membranes. c-Src and 
phosphorylated c-Src proteins were probed with rabbit anti-Src and anti-p-Src antibodies, respectively 
(both from New England Biolabs, Hitchin, UK). Mouse anti-actin antibody (Abcam, Cambridge, UK) was used 
as a loading control. The primary antibodies were visualised with enhanced chemiluminescence reactions 
(ECL Prime, GE Life Sciences, Bucks, UK) using the appropriate horse radish peroxidase conjugated 
secondary antibodies.  
 
Data Analysis  
Tail withdrawal latencies were calculated as a percentage of maximal possible effect (MPE). The %MPE is 
calculated using the following equation in which the maximum exposure time (MET) is 15 s and the basal 
latency was the time for tail withdrawal from 48oC water in the absence of drug administration: 
 
      
                          
                  
     
 
Comparison of conditioned place preference was done using preference scores, calculated by subtracting 
the time spent in the saline paired chamber from the time spent in the morphine paired chamber.  
 
Morphine dose-response relationships were fitted with a logistic equation to determine EC50 values, using 
GraphPad Prism software (La Jolla, CA, USA). 
 
 
 
 
Statistics 
Non-parametric % MPE values for tolerance studies, which do not conform to the normal distribution are 
expressed as median ± interquartile range (IQR). All other data are expressed as mean ± standard deviation 
(SD). Statistical comparisons of the development of tolerance (% MPE values) were analysed using the 
Kruskall-Wallis test. Pairwise analyses within genotypes (vs day 1) and between genotypes (on the same 
days) were compared using the Dunn’s multiple comparison correction. Other pair-wise statistical 
comparisons on parametric data (i.e. distance and time) were made using two-tailed t-tests (paired or 
unpaired, as indicated). Three or more groups were compared using one-way or two-way ANOVA, as 
appropriate. Repeated-measures ANOVA was used when data were acquired over multiple days. Post hoc 
pair-wise testing was performed using either the Dunnett’s test (one-way ANOVA), or the Bonferroni test 
(two-way ANOVA). P values of less than 0.05 were considered statistically significant. Statistical testing was 
performed using Graphpad Prism software. 
  
 
 
Results 
Src Inhibition Attenuates Morphine Analgesic Tolerance 
The subcutaneous administration of morphine caused a dose-dependent analgesia, prolonging tail 
withdrawal by C57BL/6 mice from 48oC water (fig. 2A). Consistent with a previous report,7 this effect 
depended on µ receptor expression, as evidenced by a lack of morphine (10 mg/Kg) analgesia in µ-/- mice 
(fig. 2A). Furthermore, morphine was less potent in µ+/- mice, which lack 50% of the full complement of µ 
receptors,7 without alteration of maximal efficacy (fig. 2A, and see Table 1).  
 
We examined the development of tolerance to repeated once daily injections of morphine (10 mg/Kg s.c.). 
Using this paradigm the analgesic effect declined in wild type mice over several days reflecting the gradual 
development of morphine tolerance (fig. 2B). There was a significant reduction of the prolongation of tail 
withdrawal, with respect to that recorded on day 1, on days 9 and 10 of morphine administration (P < 0.05; 
Kruskall-Wallis test; post hoc Dunn’s correction). Tolerance involves reduced µ receptor reserve through 
desensitization and endocytosis.2 Consistent with this, µ+/- mice demonstrated a significant reduction, by 
day 6 (P < 0.05; Kruskall-Wallis test; post hoc Dunn’s correction) in the morphine-evoked prolongation of 
tail withdrawal latency, with respect to that recorded on day 1. Pair-wise comparisons of tail withdrawal 
latencies revealed µ+/- mice displayed significantly more tolerance than wild type mice on days 6, 7 and 8 
(P < 0.05; Kruskall-Wallis test; post hoc Dunn’s correction; fig. 2B). Examination of the morphine dose-
response relationship in µ+/- mice on day 4 revealed a significant (Student t-test, p < 0.05) reduction in 
analgesic potency compared to morphine-naïve µ+/- mice (fig. 2C; Table 1). 
 
The multifunctional anchoring protein, β-arrestin2, participates in opioid receptor endocytosis and its 
absence leads to an up-regulation of µ receptors at the cell surface of primary afferent neurons.12 Mice 
lacking β-arrestin2 (β-arr2-/- mice) also exhibit reduced morphine tolerance.9 Consistent with these 
findings, β-arr2-/- mice, when treated once daily with morphine (10 mg/Kg s.c.), exhibited less tolerance on 
days 9 and 10 than did wild type mice (P < 0.05; Kruskall-Wallis test; post hoc Dunn’s correction; fig. 2B). β-
arr2-/- mice had an unaltered morphine dose-response relationship compared to wild type mice (Table 1) 
and increased basal latencies for tail withdrawal from 48oC water (student’s t-test p < 0.001; fig. 2D).  
 
The activation of µ receptors in primary afferent neurons leads to a β-arrestin2-dependent stimulation of c-
Src activation.12 We tested the hypothesis that c-Src contributes to the development of morphine analgesic 
tolerance using the anti-leukaemia c-Src inhibitor dasatinib, which crosses the blood brain barrier in mice.15 
When administered once daily to wild type mice, 30 min before morphine (10 mg/Kg s.c.), dasatinib (5 
mg/Kg i.p.) reduced the development of analgesic tolerance (fig. 2E). As previously observed (fig. 2B), 
morphine tolerance developed slowly in WT mice, but was nevertheless diminished by dasatinib (fig. 2E). 
The attenuation of morphine tolerance was significant on day 10 (P < 0.01; Kruskall-Wallis test; post hoc 
 
 
Dunn’s correction; fig. 2E). On day 10 vehicle treated mice exhibited morphine (10 mg/Kg s.c.) analgesia 
that had declined to a median of 51% MPE (IQR: 34-94; n = 8) of that on day 1. By contrast, dasatinib 
treated mice maintained full analgesia on day 10. The attenuation of morphine analgesic tolerance by 
dasatinib occurred without alteration of either the morphine dose-response relationship or basal 
nociception (fig. 2F).  
 
Due to the slow development of tolerance in wild type mice we examined the effects of dasatinib in µ+/- in 
which tolerance develops faster (fig. 2B). Vehicle treated µ+/- mice developed morphine tolerance from 
day 4 (p < 0.05; Kruskall-Wallis test; post hoc Dunn’s correction; fig. 3A). Dasatinib reduced morphine 
tolerance in µ+/- mice, the attenuation was significant on day 5 compared to vehicle treated µ+/- mice (P < 
0.05; Kruskall-Wallis test; post hoc Dunn’s correction; fig. 3A). By day 5 of daily morphine administration 
analgesia in µ+/- mice receiving vehicle i.p. had declined to a median of 34% MPE (IQR: 5-52; n = 8) of that 
seen on day 1. By contrast, on day 5, µ+/- mice receiving dasatinib (5 mg/Kg i.p.) 30 minutes prior to 
morphine, maintained a median of 100% MPE (IQR: 68-100; n = 8) analgesia (fig. 3A). 
 
While c-Src inhibition is considered responsible for its clinical efficacy, dasatinib also inhibits other tyrosine 
kinases.16 By comparison, PP2 is more specific and has the advantage of the inactive analogue PP3, which 
can be used as a comparator.12 We tested the inhibitory effects of dasatinib, PP2 and PP3 in SW620 colon 
cancer cells, which have high levels of basal c-Src activity.17 Consistent with their reported properties, 
dasatinib and PP2 inhibited c-Src when administered to colon cancer cells, while PP3 was inactive (fig. 3B). 
We administered PP2 or PP3 (5 mg/Kg i.p.) to µ+/- mice, once daily 30 min before morphine (10 mg/Kg 
s.c.). PP3 had no effect; the development of morphine tolerance was similar to that seen in vehicle treated 
mice. However, PP2 attenuated tolerance from day 4 when compared to PP3 treated mice (P < 0.05; 
Kruskall-Wallis test; post hoc Dunn’s correction; fig. 3C). Morphine analgesia in µ+/- mice declined to a 
median of 20% MPE (IQR: 14-25; n = 12) of its level on day 1 in mice receiving PP3. By contrast, on day 5 
µ+/- mice receiving PP2 maintained 91% MPE (IQR: 78-100; n = 12) of the analgesia seen on day 1. Neither 
dasatinib nor PP2 (or PP3) affected basal tail withdrawal when applied to µ+/- mice in the absence of 
morphine (data not shown).  
 
Src Inhibition Does Not Affect The Psychomotor Effects Of Morphine 
In addition to analgesia, morphine evokes psychomotor-stimulatory and reinforcing effects in mice.13,14 
Compared to saline injections (19 ± 4 m travelled on day 1, 30 min following injection), WT mice, 
administered morphine (10 mg/Kg s.c.), exhibited dramatically increased locomotor activity (81 ± 20 m, n = 
8, travelled on day 1, 30 min following injection), quantified by analysis of video tracking (p < 0.05, paired t-
test; fig. 4A). By contrast, locomotor stimulation was absent from µ-/- mice administered morphine (10 
mg/Kg), in which the average distances travelled were 19 ± 5 m and 17 ± 6 m on day 1, following saline and 
 
 
morphine injections (n = 7), respectively (fig. 4A). Morphine (10 mg/Kg) was without an effect on 
locomotion in µ-/- mice on all three days of administration (fig. 4B). By contrast, morphine (3 mg/Kg) 
caused a modest enhancement of locomotion in wild type mice (fig. 4C). However, there was neither an 
effect of time per se, nor a significant interaction of morphine and time (drug F1,28 = 5.8, p < 0.05, time F2,28 
= 0.98, p = 0.4, interaction F2,28 = 2.9, p = 0.07; two-way ANOVA). By contrast, repeated daily morphine (10 
mg/Kg) administration caused sensitisation of locomotor stimulation in WT mice (drug F1,28 = 72, time F2,28 = 
12, interaction F2,28 = 17, all p < 0.0005; two-way ANOVA; fig. 4D).  
 
By contrast to WT mice, morphine (10 mg/Kg) locomotor stimulation was modest in µ+/- mice and did not 
exhibit sensitisation (drug F1,28 = 36, p < 0.0001, time F2,28 = 1.7, p = 0.2, interaction F2,28 = 2.5, p = 0.1; two-
way ANOVA; fig. 4E). A higher dose of morphine (30 mg/Kg) evoked a more robust locomotor stimulation 
accompanied by sensitisation (drug F1,28 = 45, p < 0.0001, time F2,28 = 3.1, p = 0.06, interaction F2,28 = 8.4, p < 
0.001; two-way ANOVA; fig. 4 F).   
 
The psychomotor effect of morphine is also influenced by β-arrestin2 expression.13,14 In keeping with 
previous reports, β-arr2-/- mice displayed a diminished morphine (10 mg/Kg s.c.) locomotor stimulatory 
response compared to WT mice (fig. 4A). Morphine increased (p < 0.01, paired t-test) the average distance 
travelled by β-arr2-/- mice to 51 ± 19 m (n = 8) compared to 16 ± 5 m (n = 8) in β-arr2-/- mice receiving 
vehicle. When compared to the locomotor stimulation by morphine (10 mg/Kg) exhibited by wild type 
mice, the effect of morphine in  β-arr2-/- mice was significantly (p < 0.01, Student t-test) diminished. While 
there was no significant effect of the lower dose of morphine (3 mg/Kg) on locomotion in β-arr2-/- mice 
(fig. 4G), mice receiving 10 mg/Kg morphine exhibited increased locomotion and sensitization (drug F1,28 = 
31, time F2,28 = 6.7, interaction F2,28 = 21, all p < 0.005; two-way ANOVA; fig. 4H).  
 
The requirement for β-arrestin2 for the full locomotor stimulatory response to morphine (fig. 4A) has been 
linked to its role in recruiting phospho-ERK to D1 receptors in the striatum. Inhibition of mitogen-activated 
protein kinase/ERK kinase, which phosphorylates and thereby activates ERK, reduces morphine locomotor 
stimulation.14 We used dasatinib to determine whether c-Src is also involved in the stimulation of 
locomotion by morphine. When administered daily (5 mg/Kg, i.p.) either alone (n = 8) or 30 min prior to 
morphine (n = 8), dasatinib neither affected the average basal locomotion nor the average morphine 
locomotor stimulation compared to mice receiving vehicle (fig. 5A). Dasatinib had no effect on locomotion 
on any of the three days of its sole administration (fig. 5B). Furthermore, morphine (10 mg/Kg) caused 
locomotor stimulation and sensitization when administered on days 1-3 either after vehicle (drug F1,28 = 
561, time F2,28 = 18, interaction F2,28 = 72, all p < 0.0001; two-way ANOVA) or dasatinib (drug F1,28 = 64, p < 
0.0001, time F2,28 = 1.5, p = 0.24, interaction F2,28 = 11, p = 0.0003; two-way ANOVA; fig. 5C).   
 
 
 
Src Inhibition Does Not Affect Morphine Reinforcement 
Conditioned place preference represents drug reinforcement, an important component of human 
substance misuse.18 While there was no preference on day 1 of conditioning, WT mice exhibited a clear 
preference for the environment that was paired with morphine (10 mg/Kg s.c.) administration on day 5 
after conditioning (p < 0.01, one way ANOVA with post hoc Dunnett’s test vs no morphine; fig. 6A). 
Increased time spent in the morphine (10 mg/Kg) paired environment was evident throughout the 15 min 
testing period with no influence of time (drug F1,42 = 143, p < 0.0001, time F2,42 < 0.0001, p = 1.0, interaction 
F2,42 = 0.2, p = 0.86; two-way ANOVA; fig. 6B). In confirmation of the essential role for µ receptors in this 
reinforcing effect, µ-/- mice lacked preference for the morphine (10 mg/Kg) paired environment (fig. 6A 
and C). µ-/- mice spent equal times in the environments paired with either saline or morphine at all stages 
during testing (fig. 6C). Similarly, µ+/- mice exhibited no preference for the morphine (10 mg/Kg) paired 
environment (fig. 6D). Morphine preference did however become apparent throughout the 15 min period 
in µ+/- mice receiving the higher dose of 30 mg/Kg morphine (drug F1,28 = 19, p < 0.0005, time F2,28 < 0.0001, 
p = 1.0, interaction F2,28 = 1.2, p = 0.32; two-way ANOVA; fig. 6E). Comparison of the dose-dependence of 
morphine preference in µ+/- mice reveals an apparent dextral shift compared to wild type mice (fig. 6F 
versus fig. 6A) with morphine (30 mg/Kg) causing a significant preference (p < 0.01, one way ANOVA with 
post hoc Dunnett’s test vs no morphine). 
 
A previous study demonstrated that an absence of β-arrestin2 enhances the rewarding properties of 
morphine.13 In agreement with this we found that β-arr2-/- mice exhibited an increased sensitivity to 
morphine conditioned place preference (fig. 6G). Unlike wild type mice that lacked a significant response to 
3 mg/Kg morphine, the same dose caused a robust conditioned place preference in β-arr2-/- mice (p < 0.01, 
one way ANOVA with post hoc Dunnett’s test vs no morphine), which was similar to that associated with 10 
mg/Kg morphine (fig. 6G). These findings suggest that inhibition of a β-arrestin2-mediated signalling 
pathway may increase reward. We next examined whether dasatinib (5 mg/Kg i.p.) causes a similar 
increase in morphine conditioned place preference. Comparison of the dose-dependence for conditioned 
place preference reveals that, unlike the absence of β-arrestin2, which enhanced the sensitivity to 
morphine preference in β-arr2-/- mice, the dose-dependence in dasatinib treated wild type mice resembles 
that seen in untreated wild type mice, with morphine preference observed at the 10 mg/Kg dose (p < 0.01, 
one way ANOVA with post hoc Dunnett’s test vs no morphine; fig. 6H).   
 
Dasatinib Reverses Morphine Analgesic Tolerance 
Having established that dasatinib inhibits morphine tolerance without affecting reward, we explored 
whether dasatinib influences tolerance in mice in which it had already developed. µ+/- mice were given 
morphine (10 mg/Kg) daily to initiate the development of tolerance and on day 4 received either dasatinib 
or vehicle 30 min prior to morphine administration (fig. 7). Tolerance continued to develop in vehicle 
 
 
treated mice. However, dasatinib caused an immediate reversal of tolerance and attenuated its further 
development. Comparisons of analgesia on days 4 and 5 between vehicle and dasatinib treated mice 
revealed a statistically significant difference (P < 0.05; Kruskall-Wallis test; post hoc Dunn’s correction; fig. 
7).
 
 
Discussion 
This study reveals a requirement for c-Src activity for morphine analgesic tolerance and identifies c-Src 
inhibitors as agents that promote sustained analgesia. The c-Src inhibitor, dasatinib not only attenuated 
tolerance, but when administered before morphine also rapidly restored analgesia that had diminished 
during the preceding days. These effects occurred without altered psychomotor or reinforcing effects of 
morphine, suggesting that inhibitors of c-Src reduce opioid tolerance, without increasing reward.  
 
The c-Src inhibitors alone had no effect on nociception and dasatinib did not influence the dose 
dependence of analgesia by morphine. These findings suggest that tolerance is required for c-Src inhibitors 
to enhance morphine analgesia. However, it remains to be determined whether c-Src activity is necessary 
for the expression and/or the development of tolerance. It is challenging to derive mechanistic insights 
from behavioral experiments. However, in future it would be worthwhile investigating whether the reversal 
of morphine analgesic tolerance persists after elimination of the c-Src inhibitor as has been demonstrated 
in the case of an NMDA receptor antagonist.19 Such an effect would be consistent with a requirement for c-
Src activity for the development of tolerance.   
 
The non-receptor tyrosine kinase v-Src was the first retroviral oncogene to be discovered.20 Subsequent 
research identified its cellular counterpart, c-Src, in vertebrates in which it is highly enriched at the synapse 
implying a role for the kinase in regulating neurotransmission.21 G protein coupled receptors, including µ 
receptors, couple to c-Src through mechanisms that are either independent (such as a PKC-mediated 
mechanism) or dependent on β-arrestins.12,22-24 µ Receptor-mediated activation of c-Src in DRG neurones, 
which is dependent on β-arrestin2, contributes to inhibition of presynaptic voltage-activated Ca2+ channels 
through phosphorylation of a specific alternatively spliced isoform of the N-type channel.12,25 In addition to 
its immediate role in µ receptor-mediated signal transduction, β-arrestin2-dependent c-Src activity also 
participates in µ receptor endocytosis and desensitization. The c-Src inhibitor, PP2, increases surface 
expression of µ receptors in DRG neurons and decreases opioid-induced heterologous desensitization in 
locus ceruleus neurons.11,12 These mechanisms may contribute to the attenuation of morphine analgesic 
tolerance by c-Src inhibitors in vivo.  
 
Tolerance is arguably the most problematic aspect of opioid analgesia. The phenomenon leads to a 
requirement for escalating doses in patients suffering from persistent pain. Those on weak opioids often 
progress to stronger options and the continuing proliferation of prescriptions for strong opioids has led to 
their increased availability for diversion and misuse.1,4 The demonstration of a role for β-arrestin2 in 
tolerance and other side effects of opioids triggered the search for µ receptor agonists biased in favour of G 
protein stimulation.5,26-31 The first was herkinorin, which activates G proteins without recruitment of β-
arrestin2 and produces analgesia in rats with markedly decreased tolerance compared to that of 
 
 
morphine.28,29 Herkinorin also caused less respiratory depression and constipation, µ receptor mediated 
side effects of morphine that are dependent on β-arrestin2 expression.29,32 The discovery of herkinorin was 
followed by TRV130 and PZM21, additional analgesic µ receptor agonists biased against β-arrestin2 
recruitment.26,27 While the relative tendency for these agonists to cause tolerance remains unreported, 
both cause negligible β-arrestin2 recruitment and less respiratory depression and constipation than is 
associated with morphine. TRV130 performed well as an acute pain medication during bunionectomy in a 
phase 2 clinical trial.31 However, no biased µ receptor agonist has yet been tested in patients suffering from 
persistent pain. Furthermore, the extent that G protein bias plays in the apparently superior analgesic 
profiles of these new molecules compared to morphine remains unclear. An alternative explanation may be 
partial efficacy.33  
 
An alternative to developing agonists biased against β-arrestin2 is to inhibit downstream components of 
the pathway, such as c-Src; our findings suggest that this is an effective approach for attenuating opioid 
tolerance. It is advantageous that c-Src inhibition, unlike deletion of β-arrestin2, does not influence the 
reinforcing or psychomotor effects of morphine. This suggests that c-Src inhibitors are unlikely to increase 
the hedonic effects of opioids. While ERK has been implicated in mediating the influence of β-arrestin2 on 
psychomotor activation,14 the cause of the enhanced sensitivity to morphine reinforcement in β-arr2-/- 
mice remains unknown. It is possible that this reflects an upregulation of surface µ receptors and/or 
dopamine receptors in the reward pathway in the absence of β-arrestin2-dependent endocytosis. If so, our 
findings suggest that this does not involve c-Src. Additional work is required to establish whether c-Src 
participates in other side effects of morphine such as constipation and respiratory depression.  
 
While c-Src inhibitors were not anti-nociceptive in the acute pain model used in our study, c-Src activity has 
been implicated in persistent inflammatory, neuropathic and bone cancer pain, in which c-Src inhibitors 
reduce hyperalgesia.34-37 Hyperalgesia is associated with Src-mediated phosphorylation of the NMDA 
receptor, which leads to enhanced excitatory transmission in spinal neurones.34,36 Several parallels can be 
drawn between hyperalgesia and morphine tolerance, including a common requirement for NMDA 
receptor activity;38 the involvement of c-Src in both processes provides a potentially unifying mechanism. 
The ability of c-Src inhibitors to inhibit hyperalgesia and reverse tolerance, thereby restoring analgesia, 
makes them promising candidates as adjuncts to opioid analgesics.  
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 Figure legends 
Fig. 1. Pathways implicated in tolerance that converge on Src. Neurons contain high levels of c-Src.21 Recent 
studies have identified several pathways that converge on Src, their inhibition reduces morphine 
tolerance,6,38-42 potentially implicating the non-receptor tyrosine kinase as a hub in this process. Red spots 
represent targets of Src-mediated phosphorylation.24,25,43 µ Receptors (grey), the chemokine receptor type 
4 (CXCR4), the leptin receptor (LEPR), N-methyl D-aspartate receptors (NMDA-R) and platelet derived 
growth factor receptor β (PDGF-β) are depicted in grey, red, green, dark blue and light blue, respectively. β-
Arrestin2 (β-arr2), Src kinase (Src), c-Jun N-terminal kinase (JNK), mechanistic target of rapamycin (mTOR) 
and N-type Ca2+ channels (CaV2.2) are depicted in green, pink, orange, yellow and light blue, respectively. 
 
Fig. 2. Dasatinib attenuates morphine tolerance. (A) The dose-dependence of morphine prolongation of 
latency for tail withdrawal from noxious heat in wild type (n = 29) and µ+/- mice (n = 15). The ED50 was 
significantly greater in µ+/- mice (Table 1). Morphine (10 mg/Kg) had no effect on tail withdrawal latency 
when applied to µ-/- mice (n = 15). (B) The development of morphine (10 mg/Kg) analgesic tolerance in wild 
type (n = 16), µ+/- (n = 15) and -arr2-/- (n = 15) mice. Data identified with asterisks were significantly 
different from equivalent wild type data (*p < 0.05, Kruskall-Wallis test, post hoc Dunn’s correction). (C) The 
dose-dependence of morphine prolongation of latency for tail withdrawal from noxious heat in µ+/- mice, 
in which tolerance was induced by 4 once daily injections of morphine (10 mg/Kg s.c.). The morphine dose-
response relationship was examined on day 5 (n = 8). Compared to naïve MOP+/- mice, tolerance caused a 
reduction in the analgesic potency of morphine (Table 1). (D) The dose-response relationship for morphine 
in β-arr2-/- (n = 16) was similar to that of wild type mice (Table 1). Inset, tail withdrawal latency was longer 
for β-arr2-/- compared to WT mice (*p < 0.001, student’s t-test). (E) Dasatinib (5 mg/Kg i.p.), applied 30 
mins before morphine (10 mg/Kg), reduced morphine tolerance in wild type mice (n = 8) compared to 
vehicle treated controls (n = 8). Inset, the schematic represents the dosing regimen. Data identified with 
asterisks were significantly different from equivalent vehicle data (*p < 0.01, Kruskall-Wallis test, post hoc 
Dunn’s correction). (F) Dasatinib neither affected the morphine dose-response relationship nor the time for 
tail withdrawal measured in the absence of morphine (inset bar graph). Data points in (B) and (E) represent 
median values and error bars are ± IQR. All other data are expressed as mean ± SD. 
Fig. 3. Inhibition of c-Src attenuates morphine tolerance. (A) Dasatinib (n = 8) reduced tolerance in µ+/- 
mice compared to vehicle injections (n = 8). Data identified with asterisks were significantly different from 
equivalent vehicle data (*p < 0.05, Kruskall-Wallis test, post hoc Dunn’s correction). (B) Western blot 
showing total c-Src (left panel) and phosphorylated c-Src (right panel) extracted from SW620 colon cancer 
cells treated with either DMSO (vehicle), PP2 (10 μM), dasatinib (10 μM) or PP3 (10 μM). β-Actin was used 
as a loading control. PP2 and dasatinib reduced phosphorylated c-Src levels, while PP3 had no effect 
relative to vehicle. (C) The relatively selective c-Src inhibitor, PP2 (5 mg/Kg i.p.), also attenuated the 
development of morphine tolerance, while the inactive analogue, PP3 (5 mg/Kg i.p.) did not. Data identified 
 
 
with asterisks were significantly different from equivalent PP3 data (*p < 0.01, Kruskall-Wallis test, post hoc 
Dunn’s correction). Data are presented as median ± IQR. 
 
Fig. 4. Either fewer µ receptors or the absence of β-arrestin2 diminishes psychomotor stimulation by 
morphine. (A) Morphine (10 mg/Kg s.c.) stimulated locomotor activity in WT mice averaged over the 3 days 
of conditioning (*p < 0.001, n = 8, paired t-test compared to saline). This effect was not seen in µ-/- mice in 
which morphine had no effect on the averaged locomotion (n = 7). By contrast, morphine stimulated 
locomotion in -arr2-/- mice (*p < 0.01, paired t-test, n = 8), but the average distance travelled was less 
than that of WT mice (#p < 0.01, unpaired t-test). (B) Morphine (10 mg/Kg) was without effect on distance 
travelled by µ-/- mice (n = 7) on all days of conditioning. (C) Morphine (3 mg/Kg) administration to WT mice 
(n = 8) showed modest increase on distance travelled on days 2 and 3 of conditioning (*p < 0.05, two-way 
ANOVA, post hoc Bonferroni test). (D) At a higher dose morphine (10 mg/Kg s.c.) increased distance 
travelled on all 3 days and this effect exhibited sensitization (*p < 0.0001, two-way ANOVA, post hoc 
Bonferroni test; n = 8). (E) The locomotor effect of morphine (10 mg/Kg) was diminished in µ+/- mice (n = 8) 
and there was no sensitisation (*p < 0.01 on day 1, p < 0.0001 on day 2 and 3, two-way ANOVA, post hoc 
Bonferroni test). (F) A higher dose of morphine (30 mg/Kg) enhanced locomotion, but there was no effect 
of time over the 3 days of conditioning (*p < 0.0001, two-way ANOVA, post hoc Bonferroni test; n = 8). 
Morphine (3 mg/Kg) had no effect on distance travelled by β-arr2-/- mice on days 1-3 (n = 8).  (G) At a 
higher dose morphine (10 mg/Kg) increased distance travelled by β-arr2-/- mice on all 3 days and this effect 
exhibited sensitization (*p < 0.01 on day 1, p < 0.0001 on day 2 and 3, two-way ANOVA, post hoc Bonferroni 
test; n = 8). 
Fig. 5. Dasatinib does not affect psychomotor stimulation by morphine. (A) The graph of locomotion 
averaged over 3 days of conditioning with dasatinib and/or morphine. Dasatinib had no effect on 
locomotion when administered alone to wild type mice (n = 8). Dasatinib (n = 8) also had no effect 
compared to vehicle (n = 8) on the stimulation of locomotion by morphine, which was significant in both 
cases (*p < 0.001, paired t-test). (B) Dasatinib (5 mg/Kg) was without effect on distance travelled by mice (n 
= 8) on all 3 days of conditioning. (C) Morphine caused locomotor stimulation with sensitization over the 3 
days of conditioning when mice were administered either vehicle (left panel) or dasatinib (right panel) i.p 
(*p < 0.0001, two-way ANOVA, post hoc Bonferroni test).  
Fig. 6. Unlike the absence of β-arrestin2, which enhances reinforcement by morphine, dasatinib had no 
effect. (A) Morphine (3 and 10 mg/Kg s.c.) caused a dose-dependent preference of wild type mice (n = 8) 
for the paired environment (*p < 0.01, one-way ANOVA, post hoc Dunnett’s test). Morphine preference 
was lacking in µ-/- mice (n = 7). (B) Following conditioning, the duration of occupancy of the morphine-
paired environment increased significantly compared to the saline-paired environment in wild type mice at 
all three 5 min intervals (*p < 0.0001, two-way ANOVA, post hoc Bonferroni test; n = 8). (C) µ-/- mice (n = 7) 
 
 
exhibited no morphine conditioned place preference at any stage during the 15 min test period. (D) µ+/- 
mice (n = 8) also exhibited no morphine (10 mg/Kg) conditioned place preference. (E) By contrast, µ+/- mice 
(n = 8) exhibited conditioned place preference to a higher dose of morphine (30 mg/Kg) (*p < 0.05 for 300-
600 s, p < 0.001 for 600-900 s, two-way ANOVA, post hoc Bonferroni test). (F) Morphine (10 and 30 mg/Kg) 
caused a dose-dependent preference of µ+/- mice (n = 8) for the paired environment (*p < 0.05, one way 
ANOVA, post hoc Dunnett’s test). (G) Morphine preference occurred at a lower dose in -arr2-/- mice (*p < 
0.01, one way ANOVA, post hoc Dunnett’s test; n = 8). (H) By contrast, dasatinib had no effect morphine 
preference (*p < 0.01, one way ANOVA, post hoc Dunnett’s test; n = 8).  
Fig. 7. Reversal of morphine tolerance by dasatinib. The diagram depicts the morphine, dasatinib/vehicle 
injection schedule on days 1 - 5. Data in the graph are average tail withdrawal latencies expressed as 
percentage of maximal possible effect (%MPE). µ+/- mice injected with vehicle (n = 8) 30 min prior to 
morphine on days 4 and 5 continued to develop tolerance. By contrast, µ+/- mice receiving dasatinib (n = 8) 
30 min prior to morphine on days 4 and 5 exhibited reversal of analgesic tolerance. Data identified with 
asterisks were significantly different from equivalent vehicle data (*p < 0.05, Kruskall-Wallis test, post hoc 
Dunn’s correction). Data are presented as median ± IQR. 
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